Copy Link Print Information

Disitamab vedotin

(Synonyms: RC48)
5 Cited Publications
Customer Review

Based on 5 publication(s) in Google Scholar

Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Disitamab vedotin enhances antitumor immunity.

For research use only. We do not sell to patients.

  • Purity: 98.90%
  • CAS No.: 2136633-23-1
  • Molecular Weight:149000 (average)
  • Storage:

    Please store the product under the recommended conditions in the Certificate of Analysis.

  • Disitamab vedotin Chemical Structure
    Disitamab vedotin Chemical Structure
  • Experimental Validation Results for Disitamab vedotin
  • Experimental Validation Results for Disitamab vedotin
  • Experimental Validation Results for Disitamab vedotin
  • Experimental Validation Results for Disitamab vedotin
  • Experimental Validation Results for Disitamab vedotin
CAS No.: 2136633-23-1
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Purity & Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Disitamab vedotin

More
Customer Validation & Images
Cell Proliferation/Viability AssayFlow CytometryIn Vivo Efficacy StudyIHC
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • Flow Cytometry
  • In Vivo Efficacy Study
  • IHC

All EGFR Isoforms

More
Keywords
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Disitamab vedotin Chemical Structure
    Disitamab vedotin Chemical Structure
    1/16
  • 1/16

    Disitamab vedotin purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2025 Oct 10:630:217900. [Abstract]

    Customer Validation
     Disitamab vedotin (DV, 0.25 μg/mL) reduced the overall cell number of HER2-positive JIMT-1 breast cancer cells.

  • 1/16

    Disitamab vedotin purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2025 Oct 10:630:217900. [Abstract]

    Customer Validation
     Unlike the parental cells, which were sensitive to XMT-1522 and Disitamab vedotin (DV, 0.0001, 0.0006, 0.003, 0.016, 0.08, 0.4, 1, 2, and 10 μg/mL; 5 days), both D1 and D2 daughter cells that emerged from the DTP-PGCC were resistant to these drugs. D1, daughter-1 cells (one prior ADC treatment); D2, daughter-2 cells (two prior ADC treatments). ∗∗, p < 0.01; ∗∗∗, p < 0.001.

  • 1/16

    Disitamab vedotin purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2025 Jan 20:53:102284. [Abstract]

    Customer Validation
     Disitamab vedotin (DV, 50 μg/mL, 15 or 30 min) increased T-DM1 internalization into JIMT-1 breast cancer cells.

  • 1/16

    Disitamab vedotin purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2025 Jan 20:53:102284. [Abstract]

    Customer Validation
     In JIMT-1 xenografts, the combination of Disitamab vedotin (DV, 0.5 mg/kg or 5 mg/kg, administered intravenously twice at 7-day intervals) plus T-DM1, as well as DV plus T-DXd, inhibited tumor growth more effectively than the corresponding single treatments.

  • 1/16

    Disitamab vedotin purchased from MedChemExpress. Usage Cited in: Transl Oncol. 2025 Jan 20:53:102284. [Abstract]

    Customer Validation
     In macroscopic JIMT-1 xenografts, tumors that relapsed after T-DM1 treatment and subsequently responded to Disitamab vedotin (DV, 0.5 mg/kg or 5 mg/kg, administered intravenously twice at 7-day intervals) but later progressed had lost HER2 expression. A: PBS; B: relapsed after T-DM1, progressed on T-DM1; C: relapsed after T-DM1, progressed on DV; D: relapsed after T-DM1, progressed on T-DXd.

  • Disitamab vedotin